Drug intelligence / Profile preview

Lagosa Triplex

Development stage: Unknown
Lead developer: Wörwag Pharma
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Lagosa Triplex is a patent-pending dietary supplement developed by Wörwag Pharma, launched in Germany in April 2026. It features a unique 3-in-1 combination of Antarctic krill oil (SuperbaBoost), L-choline bitartrate, and milk thistle extract (standardized to silymarin). The product is designed to support the interconnected system of cardiovascular health, liver function, and lipid metabolism. The phospholipid-rich krill oil matrix significantly enhances the oral bioavailability of the lipophilic silymarin (silybin) by over 8-fold compared to standard milk thistle extract. It is administered orally as softgel capsules.

Brand names: Lagosa Triplex
Other names: Lagosa Triplex capsules

Beyond the preview

Go deeper on Lagosa Triplex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lagosa Triplex.